Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMR4HIW)

• Drug Name: Insulin-glargine Drug Info
• Synonyms: Glargine; Lantus; SoloStar; SoloStar [Insulin delivery pen]; A21-Gly-B31-Arg-B32-Arg-insulin

Indication

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Approved	[1]
Non-insulin dependent diabetes	5A11	Approved	[2]
Malaria	1F40-1F45	Phase 3	[3]
Type-1 diabetes	5A10	Phase 3	[4]
Type-2 diabetes	5A11	Application submitted	[5]

• Therapeutic Class: Hypoglycemic Agents
• Cross-matching ID:
  PubChem CID: 118984454
  CAS Number: CAS 160337-95-1
  TTD Drug ID: DMR4HIW

Molecule-Related Drug Atlas

Drug(s) Targeting Insulin (INS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Inulin	DM1Y2JH	Measure kidney function	MG02	Approved	[6]
Insulin Zinc Susp Recombinant Human	DM6MO9X	Diabetic complication	5A2Y	Approved	[6]
Insulin Susp Isophane Recombinant Human	DMW8KI7	Diabetic complication	5A2Y	Approved	[6]
Insulin determir	DM79NZ5	Diabetic complication	5A2Y	Approved	[7]
Insulin Susp Protamine Zinc Beef/Pork	DM0NATE	Diabetic complication	5A2Y	Approved	[6]
Insulin-aspart	DMX7V28	Diabetic complication	5A2Y	Approved	[6]
Insulin degludec	DMPL395	Type-1/2 diabetes	5A10-5A11	Approved	[8]
Insulin-detemir	DMOA4VW	Type-1/2 diabetes	5A10-5A11	Approved	[6]
LY2963016	DMEZ0H5	Type-1/2 diabetes	5A10-5A11	Phase 3	[9]
SAR342434	DMR0EWV	Diabetic complication	5A2Y	Phase 3	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Insulin (INS)	TTZOPHG	INS_HUMAN	Modulator	[6]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7572).
• [2] Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022 Feb 8;327(6):534-545.
• [3] ClinicalTrials.gov (NCT02059161) A Study of the Safety and Efficacy of MK-1293 Compared to Lantus in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003). U.S. National Institutes of Health.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [7] 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
• [8] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [9] Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus ) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Diabetes Obes Metab.2015 Aug;17(8):726-33.
• [10] Biosimilar insulins: a European perspective. Diabetes Obes Metab. 2015 May; 17(5): 445-451.